Hurwitz HI - Search Results

1

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology. Hatch AJ, et al. Among authors: hurwitz hi. Cancer Med. 2016 Sep;5(9):2249-60. doi: 10.1002/cam4.806. Epub 2016 Jul 27. Cancer Med. 2016. PMID: 27465221 Free PMC article.

2

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Free article. Clinical Trial.

3

Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.

Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Blackwell K, et al. Cancer. 2004 Jul 1;101(1):77-82. doi: 10.1002/cncr.20336. Cancer. 2004. PMID: 15221991 Free article. Clinical Trial.

4

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

Hurwitz H. Hurwitz H. Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S62-8. doi: 10.3816/ccc.2004.s.010. Clin Colorectal Cancer. 2004. PMID: 15479481 Review.

5

Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.

White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, Jowell PS, Clary BM, Pappas TN, Tyler DS. White RR, et al. Among authors: hurwitz hi. Ann Surg Oncol. 2005 Mar;12(3):214-21. doi: 10.1245/ASO.2005.03.105. Epub 2005 Mar 3. Ann Surg Oncol. 2005. PMID: 15827813

6

New combinations in metastatic colorectal cancer: what are our expectations?

Hurwitz H. Hurwitz H. Oncologist. 2005 May;10(5):320-2. doi: 10.1634/theoncologist.10-5-320. Oncologist. 2005. PMID: 15851788 Free article. Review. No abstract available.

7

Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.

Goldberg RM, Hurwitz HI, Fuchs CS. Goldberg RM, et al. Among authors: hurwitz hi. Clin Adv Hematol Oncol. 2005 Dec;3(12):1-10; quiz 11. Clin Adv Hematol Oncol. 2005. PMID: 16555433

8

Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

Hurwitz HI, Honeycutt W, Haley S, Favaro J. Hurwitz HI, et al. Clin Colorectal Cancer. 2006 May;6(1):66-9. doi: 10.3816/CCC.2006.n.023. Clin Colorectal Cancer. 2006. PMID: 16796794

9

The role of targeted therapy in the treatment of colorectal cancer.

Goldberg RM, Hurwitz HI, Fuchs CS. Goldberg RM, et al. Among authors: hurwitz hi. Clin Adv Hematol Oncol. 2006 Aug;4(8 Suppl 17):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2006. PMID: 17139241 Review.

10

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.

Hurwitz H, Saini S. Hurwitz H, et al. Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34. doi: 10.1053/j.seminoncol.2006.08.001. Semin Oncol. 2006. PMID: 17145522 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

211 results

Search Page